MOUNTAIN VALLEY MD HLDGS
Mountain Valley MD Holdings Inc., a biotech company, focused on advancing solutions to optimize human, animal, and plant health in Canada. The company offers Quicksome which uses proprietary formulations and stabilizing agents to encapsulate active ingredients and optimizing delivery in pharmaceutical and nutraceutical applications; and Quicksol solubility enhances solubility for previously insol… Read more
MOUNTAIN VALLEY MD HLDGS (20MP) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MOUNTAIN VALLEY MD HLDGS (20MP) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MOUNTAIN VALLEY MD HLDGS - Net Assets Trend (None–None)
This chart illustrates how MOUNTAIN VALLEY MD HLDGS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MOUNTAIN VALLEY MD HLDGS (None–None)
The table below shows the annual net assets of MOUNTAIN VALLEY MD HLDGS from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MOUNTAIN VALLEY MD HLDGS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MOUNTAIN VALLEY MD HLDGS Competitors by Market Cap
The table below lists competitors of MOUNTAIN VALLEY MD HLDGS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Logistics Vicem JSC
VN:HTV
|
$2.86 Million |
|
US Nuclear Corp
PINK:UCLE
|
$2.86 Million |
|
Saliran Group Berhad
KLSE:0346
|
$2.86 Million |
|
MCDONALD'S
MU:MDO
|
$2.86 Million |
|
Dlaboratory Sweden AB
ST:DLAB
|
$2.86 Million |
|
Compucom Software Limited
NSE:COMPUSOFT
|
$2.86 Million |
|
Axe Compute Inc.
NASDAQ:AGPU
|
$2.86 Million |
|
Imagesat International ISI Ltd
TA:ISI
|
$2.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MOUNTAIN VALLEY MD HLDGS's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MOUNTAIN VALLEY MD HLDGS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MOUNTAIN VALLEY MD HLDGS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MOUNTAIN VALLEY MD HLDGS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MOUNTAIN VALLEY MD HLDGS (20MP) | €- | N/A | N/A | $2.86 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |